{"id":"NCT01245049","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children","officialTitle":"Immunogenicity and Safety of GSK Biologicals' dTpa-IPV Vaccine (Boostrix Polio) as a Booster Dose in 3 and 4-year-old Children","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04-01","primaryCompletion":"2012-03-27","completion":"2012-04-02","firstPosted":"2010-11-22","resultsPosted":"2017-07-05","lastUpdate":"2018-08-17"},"enrollment":387,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Acellular Pertussis","Poliomyelitis","Tetanus","Diphtheria"],"interventions":[{"type":"BIOLOGICAL","name":"Boostrix PolioTM","otherNames":[]},{"type":"BIOLOGICAL","name":"RepevaxTM","otherNames":[]},{"type":"BIOLOGICAL","name":"PriorixTM","otherNames":[]}],"arms":[{"label":"BOOSTRIX POLIO GROUP","type":"EXPERIMENTAL"},{"label":"REPEVAX GROUP","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to compare the immunogenicity and safety of a booster dose of BoostrixTM Polio to that of Sanofi Pasteur MSD's RepevaxTM, when co-administered with a second dose of PriorixTM, in healthy 3 and 4-year-old children.","primaryOutcome":{"measure":"Number of Subjects With a Booster Response to Diphtheria (D) and Tetanus (T) Antigens","timeFrame":"At Month 1, one month after the booster vaccination","effectByArm":[{"arm":"Boostrix Polio Group","deltaMin":176,"sd":null},{"arm":"Repevax Group","deltaMin":90,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"3 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":15},"locations":{"siteCount":13,"countries":["United Kingdom"]},"refs":{"pmids":["29576304"],"seeAlso":["https://clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":255},"commonTop":["Redness","Pain","Irritability","Swelling","Drowsiness"]}}